NCT05687123 2026-03-18
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
25 trialsNCT05691465 2026-03-18
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05773274 2026-03-18
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04665739 2026-03-17
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03206060 2026-02-17
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06955169 2026-02-17
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
NCT04954820 2026-02-05
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT06122610 2026-01-15
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 1 Recruiting
NCT06663072 2026-01-09
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
University of Chicago
Phase 1 Recruiting
NCT04086485 2025-12-17
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06016855 2025-12-17
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 4 Recruiting
NCT04082520 2025-12-11
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
Phase 2 Recruiting
NCT05178693 2025-11-24
LANTana
Imperial College London
Phase 1 Recruiting
NCT03966651 2025-11-18
NEUROBLU 02
Institut Claudius Regaud
Phase 1 Recruiting
NCT05278208 2025-10-20
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT04609592 2025-09-09
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Phase 1 Recruiting
NCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT06395402 2025-07-22
LUMOD-ID
University of Iowa
Phase 2 Recruiting
NCT05583708 2025-05-23
iPRRT
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT06389097 2025-03-07
(SEEtoTREAT)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting
NCT04261855 2025-02-14
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Recruiting
NCT04903899 2025-02-11
LuDO-N
Karolinska University Hospital
Phase 2 Recruiting
NCT06607692 2024-10-21
LUPARPED
Fundación de investigación HM
Phase 2 Recruiting
NCT04949282 2022-12-23
SEPTRALU
Sociedad Española de Medicina Nuclear e Imagen Molecular
Recruiting